Moderna and Novavax develop coronavirus vaccine

American Moderna and Novavax companies develop Wuhan coronavirus vaccine

Patients with new coronavirus infections that originated in Wuhan, China in December 2019 have been discovered and confirmed in many countries and regions. The geographic extent of the virus's spread and its recently discovered ability to spread through human-to-human contact have caused health officials to worry about the possibility of global spread. As health officials scramble to learn more about the virus and its origins, researchers are working hard to develop vaccines or therapies that can help curb the global spread of the virus. Experts believe that this is technically feasible, but it also faces challenges.

Dr. Ralph Baric, who studies coronavirus at the School of Global Public Health at the University of North Carolina at Gillins University, said that the Wuhan virus (officially named 2019-nCoV) belongs to the coronavirus family.

This category includes SARS (Severe Acute Respiratory Syndrome), Severe Acute Respiratory Syndrome) and MERS (Middle East Respiratory Syndrome).

Although the new coronavirus is not exactly the same as SARS, their similarity allows scientists to use previous research experience and results to accelerate the development of vaccines and drugs against Wuhan coronavirus.

Dr. Anthony Fauci, long-time director of the National Institute of Allergy and Infectious Diseases (NIAID), said that after the SARS outbreak in 2003, researchers produced a vaccine and pushed it forward.

The first phase of human trials to test the safety of new drugs, but this effort has never made further progress, mainly due to the shift of research focus of participating units as the epidemic ended.

Dr. Fauci said that, theoretically, Chinese researchers have sequenced the Wuhan coronavirus. It should be fairly easy to adjust the SARS vaccine model for the unique aspects of Wuhan coronavirus.

Another option is to modify existing monoclonal antibodies that help the immune system attack foreign bodies such as viruses. "You don't want to be too optimistic, you will indeed encounter obstacles, but fundamentally and conceptually, it is not difficult to achieve this."

Dr. Fauci added that NIAID is working with Moderna, a biotechnology company in Massachusetts, to put an experimental vaccine into a clinical trial.

He estimates that this process will take about three months and cost millions of dollars.

This does not mean that people can actually be vaccinated very quickly, because the first phase of the trial is only the first step towards safe human use, usually after animal studies and before human studies of drug efficacy.

Whether these projects will proceed further depends largely on the results of the first phase of the trial, the duration and severity of the outbreak. But Dr. Fauci believes that the investment and efforts in this area are totally worthwhile.

Development of vaccines may last longer than Coronavirus Epidemic

Dr. Timothy Sheahan, who studies coronaviruses with Dr. Baric at the University of North Carolina, said that the development of vaccines may last longer than the disease. But this does not mean that the development of the remedy is not worth it.

The Ebola virus is a good example. In 2014, when the Ebola outbreak occurred in West Africa, it was too late when the drugs or vaccines were developed.

However, when Ebola virus appeared again in Congo in 2018, the drug / vaccine has been developed. This time, the crisis was promptly responded to and the public health was improved.

Biotech company Moderna is developing vaccines for Wuhan coronavirus

US government health agency to develop a Coroavirus vaccine

On January 21, 2020, Moderna, a US biotechnology company founded in 2010, said in a stock exchange report that the company is working with the US government health agency to develop a vaccine for the current Wuhan coronavirus.

Specifically, the company is collaborating with the National Institutes of Health (NIH), the National Institute of Allergy and Infectious Diseases (NIAID), and the Vaccine Research Center (VRC) to develop potential vaccines.

Moderna had produced cancer vaccine within 40 days

Moderna CEO Stephane Bancel revealed that they had produced a cancer vaccine within 40 days. They are now using the same technology for rapid development.

The company stated in a document filed with the US Securities and Exchange Commission:

“As a fast and flexible platform, Moderna’s mRNA vaccine technology is expected to be useful against emerging virus threats such as new coronaviruses.

Although we have not tested this before Rapid response capability, but Moderna confirms that it is working with NIH / NIAID / VRC to study potential vaccines for current public health emergencies. "

Depiction of Moderna and Novavax develop coronavirus vaccine

According to Amazon Web Services, Moderna is currently using Amazon's cloud platform to study more than a dozen drug candidates, seven of which are in human trials. Cloud services are used to help accelerate the process from research to clinical trials.

(Source: Official website of Moderna)

Use of use Novavax's recombinant nanoparticle vaccine technology

The company stated that they have extensive history and extensive experience in coronavirus research including MERS and SARS and in the development of candidate vaccines. The company said in a statement:

"The company hopes to use Novavax's recombinant nanoparticle vaccine technology to develop a candidate vaccine based on the gene sequence of Wuhan coronavirus."

Novavax also plans to make full use of its proprietary Matrix-M adjuvant technology to strive to further enhance the immune response.

Medical time will continue to pay close attention and report in time.

Post a comment